Loading...
Loading...
BNOX| Name | Value |
|---|---|
| Revenues | 15.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 3.0M |
| Operating I/L | 12.0M |
| Other Income/Expense | -0.8M |
| Interest Income | 0.0M |
| Pretax | 11.2M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | 11.3M |
Bionomics Limited is a clinical-stage biopharmaceutical company with a focus on developing novel drug candidates for central nervous system disorders and cancers. Their lead drug candidate, BNC210, targets social anxiety disorder and post-traumatic stress disorder. Additionally, they are developing BNC375 for cognitive impairment in Alzheimer's disease, BNC101 for cancer stem cells, and BNC105 for refractory colorectal cancer and relapsed/refractory chronic lymphocytic leukemia. The company generates revenue through the development and potential commercialization of these drug candidates, as well as through licensing agreements with partners such as Merck & Co., Inc.
